Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05150964 · ClinicalTrials.gov registry record · NA

Measuring Comfort and Clarity With Low Gain Feature in Pediatric Hearing Aid Users

A NA study, sponsored by Sonova.

Completed
Registry status
NA
Development phase
16
Enrollment target

NCT05150964: Completed NA study, sponsored by Sonova.

NCT05150964 is a NA study that has completed, run by Sonova. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05150964, a NA study, has completed, sponsored by Sonova.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

Comfort and clarity of speech will be measured in hearing impaired children age 8-17 using standard speech processing algorithm with a soft speech enhancer feature, referred to as the Adaptive Situational Gain (ASG) feature in study documents.

Primary Outcome

A familiar spondee word list is presented at varying dB (decibel) levels. Threshold is defined as the lowest dB level at which a correct response occurs for two out of three ascending trials. Testing was completed in two, two-hour test sessions occurring two weeks apart. A different fitting prescription, NAL (National Acoustic Laboratory) or DSL (Desired Sensation Level) was selected for each test session, and counterbalanced across participants. Each session consisted of testing with the ASG (A

Interventions

  • DEVICE Phonak Audeo hearing aid

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-06-01
Est. Completion 2022-05-29
Phase NA
Sonova

29 total trials

What the finished NCT05150964 record still lists

NCT05150964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Phonak Audeo hearing aid is the first listed.

NCT05150964 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05150964 about?

NCT05150964 is a clinical study titled "Measuring Comfort and Clarity With Low Gain Feature in Pediatric Hearing Aid Users". Comfort and clarity of speech will be measured in hearing impaired children age 8-17 using standard speech processing algorithm with a soft speech enhancer feature, referred to as the Adaptive Situational Gain (ASG) feature in study documents.

What is the current status of trial NCT05150964?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2021-06-01. Estimated completion is 2022-05-29.

What interventions are being tested in trial NCT05150964?

The interventions under investigation include: Phonak Audeo hearing aid (DEVICE).

Who is sponsoring clinical trial NCT05150964?

This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05150964's enrollment target sits among peer trials

16 1871st of 2000 higher than 120 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05150964, the US trial registry maintained by the National Library of Medicine. NCT05150964 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.